FDA Form 483 to Chinese Manufacturer with some alarming Observations

Recommendation
26/27 June 2025
Barcelona, Spain
Supervision of the Pharmaceutical Supply Chain: Challenges and Opportunities
The FDA carried out an inspection at Jiangsu Hengrui in January 2024. The initial findings have now been published in a so-called Form 483.
In this document, the FDA reprimanded Jiangsu Hengrui for an above-average number of manufacturing faults, but also for delays of the inspection, detours during the tour and the destruction of documents. The FDA described this process in a separate observation, noting that discarded batch records, validation reports and change controls did not always match archived official records. This attempt at ultimately delayed the entire inspection, according to the letter.
During the agency's inspection, FDA investigators noticed a large puddle of water on the floor of a warehouse and black mould-like growth on the floor near a condenser.
The observations in the manufacturing area pointed to a number of very serious problems, for example:
- Microbial contamination
- Insufficient media fills
- Inadequate container closure integrity tests
- Inadequate controls of sterile products
- Use of dirty equipment
- Insufficient cleaning validation
- Use of non-approved instructions
- Problems with data integrity
- And (unfortunately) much more
Details can be found in the document.
A Warning Letter has not yet been issued, as the company still has the opportunity to comment. However, it seems unlikely that this will not be issued.
Related GMP News
21.05.2025More FDA Warning Letters citing Quality Oversight
21.05.2025New Version of GMP Auditors Handbook available
21.05.2025FDA: more unannounced Inspections also outside the US
14.05.2025How does FDA train and guide its Inspectors?
30.04.2025QP Declaration: New Q&As published
19.03.2025Root Cause Analysis: Again, problems discovered in GMP-Inspections